ARC101 in Advanced Solid Tumors

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Third Arc Bio
Study ID
NCT06672185
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ARC101 — DRUG
    ARC101 will be administered according to an assigned dose schedule.

Study Details

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.

Key Dates

Start date
Feb 5, 2025
Status verified
Apr 2026
Primary completion
May 1, 2028
Completion
Aug 1, 2028

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation Cohorts
    ARC101 will be administered in escalating doses, with each dose escalation cohort assessing toxicity 21 days after the initial dose.
  • Experimental: Dose Expansion Cohorts
    ARC101 will be administered at recommended phase 2 dose(s).

Primary Outcome Measure

Frequency and type of dose-limiting toxicities. [ Time Frame: Day 1-Day 21 of the first treatment cycle ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Oladapo Yeku, MD (PRINCIPAL_INVESTIGATOR)
START MidwestGrand RapidsMichigan49546
Manish Sharma, MD (PRINCIPAL_INVESTIGATOR)
START San Antonio, LLC.San AntonioTexas78229
Kyriakos Papadopoulos, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital· Boston, MASTART Midwest· Grand Rapids, MISTART San Antonio, LLC.· San Antonio, TX

Related Studies